Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca teams with Heptares

AstraZeneca has teamed up with UK-based drug discovery company Heptares in a four-year collaboration to develop new therapies that target proteins linked to nervous system and cardiovascular disorders

AstraZeneca (AZ) has teamed up with UK-based drug discovery company Heptares in a four-year collaboration to develop new therapies that target proteins linked to nervous system and cardiovascular disorders.

The deal includes a £3.8m payment to Heptares, which will also be eligible for royalties from any successful products, while AZ will gain the worldwide rights.

The collaboration will make use of Heptares' G protein-coupled receptors (GPCR) discovery expertise and proprietary technologies - including its StaR technology, which engineers stabilised receptors allowing GPCRs to be investigated.

GPCRs are one of the largest family of proteins, yet have an inherent instability when removed from cell membranes, according to a statement from AZ. 

Research conducted under the collaboration will focus on a number of specific GPCR targets linked to central nervous system/pain, cardiovascular/metabolic and inflammatory disorders from projects in AZ's small and large molecule portfolio, including projects from AZ's biologics unit, MedImmune.

Martin Mackay, president of research and development, AZ, said: "Our work will focus on a range of different diseases across our small and large molecule portfolio with the goal of discovering innovative treatments for patients in areas of medical need."

31st May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CAN advertising

Brief us and you’ll soon see we really CAN do it all. We’re different to other agencies. You’ll get expert...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics